All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Lymphoma Hub Satellite Symposium 2021: Summary and roundtable discussion

On Friday, June 18, 2021, at the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub hosted a virtual satellite symposium on the sequencing of therapies in high-risk relapsed/refractory lymphoma and chronic lymphocytic leukemia (CLL).

The symposium brought together a panel of international experts, who gave their opinion on four distinct cases of patients with primary refractory diffuse large B-cell lymphoma, early relapsing follicular lymphoma, TP53-mutated mantle cell lymphoma, and ibrutinib-resistant CLL. Click to see the presentations by Andrew Davies, Loretta J. NastoupilSteven Le Gouill, and Francesc Bosch.

Below you can find the articles published by the Lymphoma Hub in the lead-up to the symposium:

The symposium concluded with an exciting roundtable discussion mediated by Lymphoma Hub Chair Gilles Salles. You can watch the discussion below, where the panelists answered questions submitted by the audience.

Satellite Symposium | Roundtable discussion, summary, and conclusions

In the lead-up to the virtual symposium, the Lymphoma Hub conducted a series of Twitter polls to gain insight into the audience’s understanding of, and interests within, the field of relapsed/refractory lymphoma (Figure 1).

Figure 1. Results of the Lymphoma Hub Satellite Symposium Twitter polls 


BTKi, Bruton’s tyrosine kinase inhibitor; CAR-T, chimeric antigen receptor T-cell therapy; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; PI3Ki, phosphoinositide 3-kinase inhibitor; R/R, relapsed/refractory.

The Lymphoma Hub would like to thank the symposium speakers and attendees for an engaging event!